CHAMBER HILL STRATEGIES for SAGHMOS THERAPEUTICS, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Policies to address health disparities in kidney disease, patient literacy, diversity in clinical trial participation, FDA/CMS communications, and Medicare payment modernization, generally, and related to the 21st Century Cures 2.0 Discussion Draft. Education and awareness, regarding treatment of contrast-induced acute kidney injury after percutaneous coronary intervention.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | Counsel, U.S. House of Representatives, Committee on Energy and Commerce |
| JENNIFER BELL | Health Policy Advisor, Sen. Finance Committee |
| ARIEL ALEJANDRO GONZALEZ | — |
Medicare/Medicaid MMM
Medicare beneficiary access to a potential treatment to prevent contrast-induced acute kidney injury and major adverse renal and cardiac events after percutaneous coronary intervention, as well as potential savings to Medicare and beneficiaries to such prevention.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | Counsel, U.S. House of Representatives, Committee on Energy and Commerce |
| JENNIFER BELL | Health Policy Advisor, Sen. Finance Committee |
| ARIEL ALEJANDRO GONZALEZ | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.